Baird analyst Joel Beatty raised the firm’s price target on BioMarin to $127 from $112 and keeps an Outperform rating on the shares. The analyst said we’re encouraged by revenue of $596M beating consensus of $570M, particularly because the biggest contributor the beat was growth in Voxzogo which is in early launch.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BMRN:
- BioMarin Announces Record Breaking First Quarter 2023 Results, Including 15% Year-over-year Growth of Total Revenues
- BioMarin sees FY23 adjusted EPS $1.80-$2.05, consensus 95c
- BioMarin reports Q1 adjusted EPS 60c, consensus 18c
- William Blair biotech analyst to hold an analyst/industry conference call
- BioMarin granted orphan status for DMD treatment